Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Satoshi Kamidani, MD, PhD

Assistant Professor of Pediatrics in Infectious Diseases
Emory University School of Medicine and Children's Healthcare of Atlanta
Suwanee, GA, United States

Satoshi Kamidani, MD, PhD is an Assistant Professor of Pediatrics at Emory University School of Medicine and an Attending Physician in Pediatric Infectious Diseases at Children’s Healthcare of Atlanta. He is the Associate Director of the Emory Children’s Center - Vaccine Research Clinic and a guest researcher at the Immunization Safety Office in the CDC. He completed his medical and PhD degrees at the University of Toyama in Japan. Dr. Kamidani’s career began as a practicing pediatrician in Japan, followed by a move to the U.S. where he completed his second residency in Pediatrics at the University of Colorado, and his fellowship in Pediatric Infectious Diseases at Emory University. Dr. Kamidani focuses his research on the epidemiology of vaccine-preventable diseases, vaccine safety, and vaccine clinical trials. He has served as an Investigator of the Emory Vaccine and Treatment Evaluation Unit (VTEU) and has been actively involved in VTEU and industry-sponsored clinical trials, including COVID-19 and RSV vaccines. In addition, Dr. Kamidani serves as the Emory site Principal Investigator of the CDC Overcoming COVID-19 Project to assess COVID-19 vaccine effectiveness in children and adolescents. Dr. Kamidani has also served as a member of the CDC’s Clinical Immunization Safety Assessment (CISA) Multisystem Inflammatory Syndrome in Children (MIS-C) Work Group, as well as a member of CDC's Advisory Committee on Immunization Practices (ACIP) MMR Vaccine Work Group as a vaccine safety expert.

Disclosure(s): Emergent BioSolutions, Inc.: My institution received funding to conduct a vaccine trial. (Terminated, September 18, 2023); Meissa Vaccine: My institution received funding to conduct a vaccine trial. (Ongoing); Pfizer, Inc.: My institution received funding to conduct Pfizer COVID-19 vaccine trials. (Ongoing)

Presentation(s):